Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records

BackgroundBranch retinal vein occlusion (BRVO) can cause visual loss through macular oedema.Routine-care outcomes reflect heterogeneous treatment histories and follow-up.This study evaluated visual and anatomical changes and their association in a district-hospital BRVO cohort. MethodsWe retrospectively analysed 102 eye records classified into 11 treatment pathways within a five-year period from January 2019 to December 2023.Visual acuity (VA), recorded in letters, and five-field average optical coherence tomography (OCT) thickness were compared between baseline and the last recorded appointment with a minimum of four weeks of follow-up.Mean changes were calculated with 95% confidence intervals (CIs).Pearson and Spearman correlations assessed the association between VA gain and OCT thickness reduction.Treatment groups were described without causal comparisons. ResultsMedian follow-up was 23 months (interquartile range, 12-38.5;range, 2-73).Mean VA increased from 60.0 ± 17.0 to 72.3 ± 13.8 letters; mean change was 12.3 ± 16.7 letters (95% CI, 9.0-15.5).Mean five-field average OCT thickness declined from 414.5 ± 109.5 to 300.5 ± 55.7 µm; mean reduction was 113.9 ± 125.2 µm (95% CI, 89.4-138.5).Forty-two eye records (41.2%) gained at least 15 letters, and four (3.9%) lost at least 15 letters.VA gain correlated with thickness reduction (Pearson r = 0.54; 95% CI, 0.38-0.66;Spearman ρ = 0.59).Exclusion of two zero-letter baseline records yielded a mean gain of 11.8 ± 16.5 letters.The aflibercept and ranibizumab categories comprised 35 and 30 records, respectively. ConclusionsVisual improvement and reduced five-field average OCT thickness were observed during routine BRVO care, with a moderate association between functional and anatomical change.Ranibizumab showed the largest mean VA gain amongst the single-agent treatment groups, exceeding the observed aflibercept.Variable follow-up, small treatment subgroups, and non-random treatment selection limit comparative interpretation.The findings support assessing vision and retinal anatomy together and do not establish superiority of any treatment pathway.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-14
DOI
https://doi.org/10.7759/cureus.119647
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records

Suki Bernstein, Cora Berdejo
2 links
Cureus
Retinal Diseases and Treatments
article

Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records

Suki Bernstein, Cora Berdejo
article en

Abstract

BackgroundBranch retinal vein occlusion (BRVO) can cause visual loss through macular oedema.Routine-care outcomes reflect heterogeneous treatment histories and follow-up.This study evaluated visual and anatomical changes and their association in a district-hospital BRVO cohort. MethodsWe retrospectively analysed 102 eye records classified into 11 treatment pathways within a five-year period from January 2019 to December 2023.Visual acuity (VA), recorded in letters, and five-field average optical coherence tomography (OCT) thickness were compared between baseline and the last recorded appointment with a minimum of four weeks of follow-up.Mean changes were calculated with 95% confidence intervals (CIs).Pearson and Spearman correlations assessed the association between VA gain and OCT thickness reduction.Treatment groups were described without causal comparisons. ResultsMedian follow-up was 23 months (interquartile range, 12-38.5;range, 2-73).Mean VA increased from 60.0 ± 17.0 to 72.3 ± 13.8 letters; mean change was 12.3 ± 16.7 letters (95% CI, 9.0-15.5).Mean five-field average OCT thickness declined from 414.5 ± 109.5 to 300.5 ± 55.7 µm; mean reduction was 113.9 ± 125.2 µm (95% CI, 89.4-138.5).Forty-two eye records (41.2%) gained at least 15 letters, and four (3.9%) lost at least 15 letters.VA gain correlated with thickness reduction (Pearson r = 0.54; 95% CI, 0.38-0.66;Spearman ρ = 0.59).Exclusion of two zero-letter baseline records yielded a mean gain of 11.8 ± 16.5 letters.The aflibercept and ranibizumab categories comprised 35 and 30 records, respectively. ConclusionsVisual improvement and reduced five-field average OCT thickness were observed during routine BRVO care, with a moderate association between functional and anatomical change.Ranibizumab showed the largest mean VA gain amongst the single-agent treatment groups, exceeding the observed aflibercept.Variable follow-up, small treatment subgroups, and non-random treatment selection limit comparative interpretation.The findings support assessing vision and retinal anatomy together and do not establish superiority of any treatment pathway.

Cureus
George Eliot Hospital (GB), Warwick Hospital (GB), Warwickshire Hospital (GB), George Eliot Hospital NHS Trust (GB)
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon